{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:39:06Z","timestamp":1782808746236,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T00:00:00Z","timestamp":1477267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T00:00:00Z","timestamp":1477267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1038\/ijo.2016.185","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T07:42:43Z","timestamp":1477294963000},"page":"90-93","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Effect of phentermine on weight reduction in a pediatric weight management clinic"],"prefix":"10.1038","volume":"41","author":[{"given":"J R","family":"Ryder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kaizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K D","family":"Rudser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A S","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C K","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,24]]},"reference":[{"key":"BFijo2016185_CR1","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/ijo.2016.69","volume":"40","author":"AS Kelly","year":"2016","unstructured":"Kelly AS, Fox CK, Rudser KD, Gross AC, Ryder JR . Pediatric obesity pharmacotherapy: Current state of the field, review of the literature, and clinical trial considerations. Int J Obes (Lond) 2016; 40: 1043\u20131050.","journal-title":"Int J Obes (Lond)"},{"key":"BFijo2016185_CR2","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1542\/peds.2007-2329C","volume":"120","author":"SE Barlow","year":"2007","unstructured":"Barlow SE . Expert Committee Recommendations Regarding the Prevention, Assessment, and Treatment of Child and Adolescent Overweight and Obesity: Summary Report. Pediatrics 2007; 120: S164\u2013S192.","journal-title":"Pediatrics"},{"key":"BFijo2016185_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ijo.2012.144","volume":"37","author":"R Sherafat-Kazemzadeh","year":"2013","unstructured":"Sherafat-Kazemzadeh R, Yanovski SZ, Yanovski JA . Pharmacotherapy for childhood obesity: present and future prospects. Int J Obes (Lond) 2013; 37: 1\u201315.","journal-title":"Int J Obes (Lond)"},{"key":"BFijo2016185_CR4","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/oby.2009.69","volume":"17","author":"EJ Hendricks","year":"2009","unstructured":"Hendricks EJ, Rothman RB, Greenway FL . How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring) 2009; 17: 1730\u20131735.","journal-title":"Obesity (Silver Spring)"},{"key":"BFijo2016185_CR5","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1001\/archinte.163.9.1046","volume":"163","author":"RS Stafford","year":"2003","unstructured":"Stafford RS, Radley DC . National trends in antiobesity medication use. Arch Intern Med 2003; 163: 1046\u20131050.","journal-title":"Arch Intern Med"},{"key":"BFijo2016185_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/adc.41.217.309","volume":"41","author":"J Lorber","year":"1966","unstructured":"Lorber J . Obesity in childhood. A controlled trial of anorectic drugs. Arch Dis Childhood 1966; 41: 309\u2013312.","journal-title":"Arch Dis Childhood"},{"key":"BFijo2016185_CR7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/000992286800700305","volume":"7","author":"JL Rauh","year":"1968","unstructured":"Rauh JL, Lipp R . Chlorphentermine as an anorexigenic agent in adolescent obesity. Report of its efficacy in a double-blind study of 30 teenagers. Clin Pediatr 1968; 7: 138\u2013140.","journal-title":"Clin Pediatr"},{"key":"BFijo2016185_CR8","unstructured":"Team RCR: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, 2015."},{"key":"BFijo2016185_CR9","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/j.1463-1326.2010.01242.x","volume":"12","author":"JG Kang","year":"2010","unstructured":"Kang JG, Park CY, Kang JH, Park YW, Park SW . Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. Diabetes Obes Metab 2010; 12: 876\u2013882.","journal-title":"Diabetes Obes Metab"},{"key":"BFijo2016185_CR10","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1038\/oby.2011.94","volume":"19","author":"EJ Hendricks","year":"2011","unstructured":"Hendricks EJ, Greenway FL, Westman EC, Gupta AK . Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring) 2011; 19: 2351\u20132360.","journal-title":"Obesity (Silver Spring)"},{"key":"BFijo2016185_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1001\/jamapediatrics.2013.1045","volume":"167","author":"AS Kelly","year":"2013","unstructured":"Kelly AS, Rudser KD, Nathan BM, Fox CK, Metzig AM, Coombes BJ et al. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr 2013; 167: 355\u2013360.","journal-title":"JAMA Pediatr"},{"key":"BFijo2016185_CR12","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/oby.2011.337","volume":"20","author":"AS Kelly","year":"2012","unstructured":"Kelly AS, Metzig AM, Rudser KD, Fitch AK, Fox CK, Nathan BM et al. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity (Silver Spring) 2012; 20: 364\u2013370.","journal-title":"Obesity (Silver Spring)"},{"key":"BFijo2016185_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2337\/db10-1185","volume":"60","author":"JA Yanovski","year":"2011","unstructured":"Yanovski JA, Krakoff J, Salaita CG, McDuffie JR, Kozlosky M, Sebring NG et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes 2011; 60: 477\u2013485.","journal-title":"Diabetes"},{"key":"BFijo2016185_CR14","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","volume":"293","author":"JP Chanoine","year":"2005","unstructured":"Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005; 293: 2873\u20132883.","journal-title":"JAMA"},{"key":"BFijo2016185_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/archpediatrics.2010.111","volume":"164","author":"DM Wilson","year":"2010","unstructured":"Wilson DM, Abrams SH, Aye T, Lee PD, Lenders C, Lustig RH et al. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med 2010; 164: 116\u2013123.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"BFijo2016185_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.amjcard.2003.09.065","volume":"93","author":"I Antelmi","year":"2004","unstructured":"Antelmi I, de Paula RS, Shinzato AR, Peres CA, Mansur AJ, Grupi CJ . Influence of age, gender, body mass index, and functional capacity on heart rate variability in a cohort of subjects without heart disease. Am J Cardiol 2004; 93: 381\u2013385.","journal-title":"Am J Cardiol"},{"key":"BFijo2016185_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/ijo.2013.74","volume":"38","author":"EJ Hendricks","year":"2014","unstructured":"Hendricks EJ, Srisurapanont M, Schmidt SL, Haggard M, Souter S, Mitchell CL et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int J Obes (Lond) 2014; 38: 292\u2013298.","journal-title":"Int J Obes (Lond)"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ijo2016185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ijo2016185","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ijo2016185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T19:25:49Z","timestamp":1647372349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ijo2016185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,24]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["BFijo2016185"],"URL":"https:\/\/doi.org\/10.1038\/ijo.2016.185","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,24]]},"assertion":[{"value":"28 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Kelly serves as a consultant for Novo Nordisk Pharmaceuticals, but does not receive personal or professional income for these activities. Dr Kelly receives research support in the form of drug\/placebo from Astra Zeneca Pharmaceuticals. Dr Fox serves as a site principal investigator for a clinical trial sponsored by Novo Nordisk Pharmaceuticals. The other authors declare no conflict of interest. No honorarium, grant or other form of payment was given to anyone to produce the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}